Specialty Investments - Litigation, Royalties, Art, Carbon Credits

By EC Assets Research Team, Specialty Alternatives · Published 19 May 2026 · Updated 15 June 2026

Specialty Investments — Specialty investments are alternative assets that don't fit conventional categories: litigation finance, music and pharmaceutical royalties, fine art, carbon credits, weather derivatives. Each is a small specialised market with unique return drivers and limited institutional capacity.

Definition

Specialty investments are alternative-asset strategies that don't fit cleanly into the major categories (hedge funds, private equity, real estate, commodities, infrastructure). The category is deliberately heterogeneous, including litigation finance, music and pharmaceutical royalties, fine art, carbon credits, weather derivatives, life settlements, agricultural land, and other niche markets.

What unifies these strategies is not a common return mechanism but a common operational profile. They all share three structural features: returns weakly correlated with traditional asset classes (which is the reason institutions consider them), capacity constraints that prevent large institutional allocation (which is the reason they remain relatively unknown), and specialised expertise required to evaluate (which is the reason most allocators outsource to specialists).

Specialty allocations are typically small as a percentage of total portfolio (1-5% combined across multiple specialty strategies). The category's role is diversification of return sources rather than alpha generation, though specific specialty managers can deliver meaningful absolute returns within their domains.

The Main Sub-Categories

Litigation Finance: A Worked Sub-Category

Litigation finance illustrates the typical specialty-investment economic structure:

A funder provides capital (typically $1-50M per case) to a plaintiff to pursue a commercial, intellectual-property, or insolvency-related claim. The capital is non-recourse - if the case loses or settles for less than expected, the funder loses the investment without recourse against the plaintiff. If the case wins, the funder receives a pre-agreed share of the award (typically 30-50%) or a multiple of capital invested (typically 2-4x), whichever is greater.

Diversified portfolios of 30-100 cases produce more stable returns than any single case. Top-quartile litigation finance managers have delivered 18-25% net IRR over rolling decade periods. The category grew from a few hundred million in AUM around 2010 to over $15 billion by 2024 as institutional adoption accelerated.

[!example] A typical litigation finance fund might commit $50M to a case expected to take 3 years. If the case settles for $300M, the funder receives the greater of: 35% of recovery ($105M) or 3x capital ($150M). The investor's IRR on this single case is approximately 44% annualised. If the case fully loses, the investor loses the $50M. A portfolio of 30 such cases with a 70% success rate produces expected portfolio IRRs in the 15-20% range with much lower variance than any single case.

Royalty Investments

Music and pharmaceutical royalties have institutionalised as separate but related sub-categories:

Music royalties. Investors acquire catalogues of music publishing rights or master recordings. Cash flows derive from streaming, licensing for film and television, and synchronisation fees. The post-streaming era stabilised music industry economics - streaming produces predictable, growing cash flows from established catalogues. Royalty Pharma, Hipgnosis Songs Fund, Round Hill, and several private funds institutionalised the space.

Pharmaceutical royalties. Investors acquire rights to a percentage of future sales from specific drugs. Cash flows are stable while patents protect the drug; they collapse at the patent cliff (typically 10-15 years post-launch). Royalty Pharma (NYSE: RPRX) is the largest specialised pharmaceutical-royalty company; multiple private funds operate in the space.

Fine Art

Fine art has a distinctive return profile that creates both opportunities and challenges as an institutional allocation:

Long-run returns are 5-8% real per year for diversified fine-art portfolios, comparable to long-run real returns on equities but with materially higher idiosyncratic risk. Individual pieces vary enormously; the Mei Moses Art Index and similar benchmarks aggregate broad categories.

The structural challenges are operational: transaction costs of 10-25% per sale (auction house commissions on both sides), no daily price discovery, authentication and provenance risk, storage and insurance costs, and limited financing or hedging capacity. Most institutional 'art allocation' is small or absent; the category remains dominated by individual collectors and family offices.

Common Misconceptions

"Specialty investments are alpha-generating." Sometimes, but more commonly they are diversifying. The category's institutional case is uncorrelated return streams, not above-average returns. Allocators expecting alpha from specialty allocations are usually disappointed.

"All uncorrelated assets are interchangeable." Different specialty categories have very different operational profiles, liquidity, and risk characteristics. Litigation finance has 2-3 year hold periods and binary outcomes; royalty investments have 10-15 year cash flows; fine art has decade-plus holds with no interim cash flows. Treating them as a homogeneous "uncorrelated" bucket misses important differences.

"Carbon credits are environmentally meaningful." Compliance carbon (EU ETS, California, RGGI) generally is - these markets price emissions and create economic pressure to reduce them. Voluntary carbon, after 2023 quality investigations, faces real questions about whether many credits represent the emissions reductions claimed. Institutional carbon investments now focus primarily on compliance markets pending voluntary-market reform.

Comparison Across Specialty Sub-Categories

Each specialty category has distinct risk-return characteristics:

The lower correlations and modest capacity are what make these strategies valuable to institutional portfolios that already have substantial allocations to traditional alternatives.

The Capacity Question

Most specialty strategies have small absolute capacity ceilings. Litigation finance globally is $15B AUM - comparable to a single large hedge fund. Music royalties similar. Even pharmaceutical royalties at $30B is small relative to institutional alternative AUM of $5T+.

The implication: a $100M institutional allocation to litigation finance is significant relative to manager capacity. Multi-billion-dollar institutions cannot make meaningful specialty allocations without concentrating heavily in single managers. This is the structural reason specialty allocations remain small percentages of institutional portfolios despite their attractive return characteristics.

References

1. Anson, M. J. P. (2006). Handbook of Alternative Assets (2nd ed.). Wiley.
2. CAIA Association. CAIA Curriculum.